APGN logo

Apexigen (APGN) Stock

Profile

Full Name:

Apexigen, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

22 February 2021

Indexes:

Not included

Description:

Apexigen, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody therapeutics for oncology. It develops a pipeline of product candidates, including APX005M, a humanized agonist antibody that is in Phase II clinical development for the treatment of solid tumors, such as melanoma, esophageal and gastroesophageal junction, sarcoma, and ovarian cancers in combination with immunotherapy, chemotherapy, radiation therapy, and cancer vaccines; and APX601, a humanized antagonist antibody that is in Phase I/II clinical trial for the treatment of multiple tumor indications, as well as APX801, an NK cell engager to activate natural killer cells to killing of tumor cells. Apexigen, Inc. was founded in 2010 and is headquartered in San Carlos, California. As of August 23, 2023, Apexigen, Inc. operates as a subsidiary of Pyxis Oncology, Inc..

Events Calendar

Earnings

Next earnings date:

N/A

Recent quarterly earnings:

Nov 14, 2023

Recent annual earnings:

N/A
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

26 May '23 EF Hutton
Hold
24 May '23 EF Hutton
Hold
16 May '23 EF Hutton
Buy
05 Jan '23 EF Hutton
Buy

Screeners with APGN included

No data

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

Similar stocks

Apexigen (APGN) to Get Acquired by Pyxis Oncology, Stock Up
Apexigen (APGN) to Get Acquired by Pyxis Oncology, Stock Up
Apexigen (APGN) to Get Acquired by Pyxis Oncology, Stock Up
APGN
Zacks Investment Research25 May 2023

Apexigen (APGN) surges as Pyxis Oncology offers to acquire it for approximately $16 million.

Why Is Apexigen (APGN) Stock Up 31% Today?
Why Is Apexigen (APGN) Stock Up 31% Today?
Why Is Apexigen (APGN) Stock Up 31% Today?
APGN
InvestorPlace24 May 2023

Apexigen (NASDAQ: APGN ) stock is rising higher on Wednesday following news of a deal with Pyxis Oncology (NASDAQ: PYXS ). This deal has Pyxis Oncology agreeing to acquire Apexigen for 0.1725 shares of PYXS stock for each share of APGN stock.

FAQ

  • What is the primary business of Apexigen?
  • What is the ticker symbol for Apexigen?
  • Does Apexigen pay dividends?
  • What sector is Apexigen in?
  • What industry is Apexigen in?
  • What country is Apexigen based in?
  • When did Apexigen go public?
  • Is Apexigen in the S&P 500?
  • Is Apexigen in the NASDAQ 100?
  • Is Apexigen in the Dow Jones?
  • When was Apexigen's last earnings report?
  • When does Apexigen report earnings?
  • Should I buy Apexigen stock now?

What is the primary business of Apexigen?

Apexigen, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody therapeutics for oncology. It develops a pipeline of product candidates, including APX005M, a humanized agonist antibody that is in Phase II clinical development for the treatment of solid tumors, such as melanoma, esophageal and gastroesophageal junction, sarcoma, and ovarian cancers in combination with immunotherapy, chemotherapy, radiation therapy, and cancer vaccines; and APX601, a humanized antagonist antibody that is in Phase I/II clinical trial for the treatment of multiple tumor indications, as well as APX801, an NK cell engager to activate natural killer cells to killing of tumor cells. Apexigen, Inc. was founded in 2010 and is headquartered in San Carlos, California. As of August 23, 2023, Apexigen, Inc. operates as a subsidiary of Pyxis Oncology, Inc..

What is the ticker symbol for Apexigen?

The ticker symbol for Apexigen is NASDAQ:APGN

Does Apexigen pay dividends?

No, Apexigen does not pay dividends

What sector is Apexigen in?

Apexigen is in the Healthcare sector

What industry is Apexigen in?

Apexigen is in the Biotechnology industry

What country is Apexigen based in?

Apexigen is headquartered in United States

When did Apexigen go public?

Apexigen's initial public offering (IPO) was on 22 February 2021

Is Apexigen in the S&P 500?

No, Apexigen is not included in the S&P 500 index

Is Apexigen in the NASDAQ 100?

No, Apexigen is not included in the NASDAQ 100 index

Is Apexigen in the Dow Jones?

No, Apexigen is not included in the Dow Jones index

When was Apexigen's last earnings report?

Apexigen's most recent earnings report was on 14 November 2023

When does Apexigen report earnings?

The date for Apexigen's next earnings report has not been announced yet

Should I buy Apexigen stock now?

As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions